Cited by 245Blood Coagulation and Thrombosis MechanismsProtease and Inhibitor MechanismsCoagulation, Bradykinin, Polyphosphates, and Angioedema

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels

Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., Juhan-Vague, I.·1997·Circulation

DOI 10.1161/01.cir.96.3.761

Open this paper in CoChat — free account

Abstract

Background To evaluate the effect of plasminogen activator inhibitor type 1 (PAI-1) levels on the clearance of total tissue plasminogen activator (TPA) antigen, we studied the clearance of active TPA and TPA/PAI-1 complex in subjects with low (181±109 pmol/L; n=7) and high (1166±322 pmol/L; n=4) baseline active PAI-1. Methods and Results A 5-μg/kg bolus of TPA was infused over a 15-second period followed by measurement of TPA activity, TPA antigen, TPA/PAI-1, TPA/C1 inhibitor, PAI-1 activity, and PAI-1 antigen over a 4-hour period. α-Phase clearance of total TPA antigen was faster in subjects with low PAI-1 (t 1/2 of 3.5±0.7 minutes) versus high PAI-1 (t 1/2 of 5.3±0.9 minutes) ( P =.006). Clearance of all factors was best fit by a two-compartment pharmacokinetic model based on a computer-simulated human circulatory system. The average hepatic clearance fraction in the two-compartment model was greater for active TPA (89±10%, t 1/2 of 2.4±0.3 minutes) than for TPA/PAI-1 complex (48±17%, t 1/2 of 5.0±1.8 minutes) ( P =.0006). Conclusions Plasma clearance of active TPA was faster than clearance of TPA/PAI-1 complex. High levels of active PAI-1 converted more TPA into TPA/PAI-1 complex, effectively slowing the clearance of total TPA antigen and explaining in part why high levels of PAI-1 activity are associated with increases in total TPA antigen.

Integrity signals

Registry

Crossref · 10.1161/01.cir.96.3.761

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Hemostatic Factors and the Risk of Myocardial Infarction or Sudden Death in Patients with Angina Pectoris
Thompson, S. G., Kienast, J., Pyke, S., Haverkate, F., & van de Loo, J. C. W. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503093321003 · Cited by 1,819
PLASMINOGEN ACTIVATOR INHIBITOR IN PLASMA: RISK FACTOR FOR RECURRENT MYOCARDIAL INFARCTION
Hamsten, A., Walldius, G., Szamosi, A., Blombäck, M., de Faire, U., Dahlén, G. H., Landou, C., & Wiman, B. (1987) · The Lancet · doi:10.1016/s0140-6736(87)93050-9 · Cited by 1,474
Blood Transfusion in Clinical Medicine.
(1952) · JAMA · doi:10.1001/jama.1952.03680120098032 · Cited by 1,290
Enhanced expression of PAI–1 in visceral fat: Possible contributor to vascular disease in obeisty
Shimomura, I., Funahasm, T., Takahashi, M., Maeda, K., Kotani, K., Nakamura, T., Yamashita, S., Miura, M., Fukuda, Y., Takemura, K., et al. (1996) · Nature Medicine · doi:10.1038/nm0796-800 · Cited by 889
Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study
MEADE, T. (1993) · The Lancet · doi:10.1016/0140-6736(93)92062-x · Cited by 711
Production of Plasminogen Activator Inhibitor 1 by Human Adipose Tissue: Possible Link Between Visceral Fat Accumulation and Vascular Disease
Alessi, M., Peiretti, F., Morange, P., Henry, M., Nalbone, G., & Juhan-Vague, I. (1997) · Diabetes · doi:10.2337/diab.46.5.860 · Cited by 614
Self-citation
Endogenous tissue-type plasminogen activator and risk of myocardial infarction
Ridker, P. M., Vaughan, D. E., Manson, J., Hennekens, C. H., & Stampfer, M. (1993) · The Lancet · doi:10.1016/0140-6736(93)90998-v · Cited by 580
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma
Kruithof, E. K. O., Trân-Thang, C., Ransijn, A., & Bachmann, F. (1984) · Blood · doi:10.1182/blood.v64.4.907.bloodjournal644907 · Cited by 400
An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation.
Cesarman, G., Guevara, C. A., & Hajjar, K. A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)31948-8 · Cited by 342
Distribution and regulation of plasminogen activator inhibitor-1 in murine adipose tissue in vivo. Induction by tumor necrosis factor-alpha and lipopolysaccharide.
Samad, F., Yamamoto, K., & Loskutoff, D. J. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118404 · Cited by 301
Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease. A 7-year follow-up.
Jansson, J.-H., Olofsson, B. O., & Nilsson, T. (1993) · Circulation · doi:10.1161/01.cir.88.5.2030 · Cited by 241
Elaboration of Type-1 Plasminogen Activator Inhibitor From Adipocytes
Lundgren, C. H., Brown, S. L., Nordt, T. K., Sobel, B. E., & Fujii, S. (1996) · Circulation · doi:10.1161/01.cir.93.1.106 · Cited by 224
Plasma plasminogen activator inhibitor-1 in angina pectoris. Influence of plasma insulin and acute-phase response.
Juhan-Vague, I., Alessi, M., Joly, P., Thirion, X., Vague, P., Declerck, P. J., Serradimigni, A., & Collen, D. (1989) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.9.3.362 · Cited by 201
Self-citation
Plasminogen Activator Inhibitor 1: Biosynthesis and mRNA Level Are Increased by Insulin in Cultured Human Hepatocytes
Kooistra, T., Bosma, P. J., Töns, H. A. M., van den Berg, A. P., Meyer, P., & Princen, H. M. G. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646891 · Cited by 182
Tissue plasminogen activator and other risk factors as predictors of cardiovascular events in patients with severe angina pectoris
Jansson, J., Nilsson, T., & OLOFSSON, B. O. (1991) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a059862 · Cited by 174
Kinetic analysis of the interactions between plasminogen activator inhibitor 1 and both urokinase and tissue plasminogen activator
Hekman, C. M., & Loskutoff, D. J. (1988) · Archives of Biochemistry and Biophysics · doi:10.1016/0003-9861(88)90182-8 · Cited by 147
Interactions of tissue-type plasminogen activator with plasma inhibitors and their pharmacologic implications.
Lucore, C. L., & Sobel, B. E. (1988) · Circulation · doi:10.1161/01.cir.77.3.660 · Cited by 138
Blood Collection in Strong Acidic Citrate Anticoagulant Used in a Study of Dietary Influence on Basal tPA Activity
Rånby, M., Sundell, I. B., & Nilsson, T. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651028 · Cited by 134
Isolation of tissue-type plasminogen activator-inhibitor complexes from human plasma
Thorsen, S., & Philips, M. (1984) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/0304-4165(84)90040-0 · Cited by 128
Inhibition of plasminogen activators by conditioned medium of human hepatocytes and hepatoma cell line Hep G2.
Sprengers, E. D., Princen, H. M., Kooistra, T., & van Hinsbergh, V. W. M. (1985) · PubMed · Cited by 128
Haemostasis Factors in Angina Pectoris; Relation to Gender, Age and Acute-phase Reaction
Haverkate, F., Thompson, S. G., & Duckert, F. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653821 · Cited by 127
Effect of PAI-1 levels on the molar concentrations of active tissue plasminogen activator (t-PA) and t-PA/PAI-1 complex in plasma
Chandler, W. L., Trimble, S., Loo, S., & Mornin, D. (1990) · Blood · doi:10.1182/blood.v76.5.930.930 · Cited by 111
Self-citation
Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products
van Hinsbergh, V. W. M., Bauer, K. A., Kooistra, T., Kluft, C., Dooijewaard, G., Sherman, M., & Nieuwenhuizen, W. (1990) · Blood · doi:10.1182/blood.v76.11.2284.2284 · Cited by 107
Plasminogen activator in normal subjects after exercise and venous occlusion: t-PA circulates as complexes with C1-inhibitor and PAI-1
Booth, N. A., Walker, E., Maughan, R. J., & Bennett, B. (1987) · Blood · doi:10.1182/blood.v69.6.1600.1600 · Cited by 95
Pharmacokinetics and systemic effects of tissue-type plasminogen activator in normal subjects
Tanswell, P., Seifried, E., Su, P. C. A. F., Feuerer, W., & Rijken, D. C. (1989) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1989.120 · Cited by 89
Hepatic Clearance of Tissue-Type Plasminogen Activator in Rats
Emeis, J. J., van den Hoogen, C. M., & Jense, D. (1985) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1660092 · Cited by 89
Immunoreactivity of Tissue Plasminogen Activator and of Its Inhibitor Complexes
Rånby, M., Nguyen, G., Scarabin, P., & Samama, M. M. (1989) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646605 · Cited by 88
The Circulatory Regulation of TPA and UPA Secretion, Clearance, and Inhibition During Exercise and During the Infusion of Isoproterenol and Phenylephrine
Chandler, W. L., Levy, W. C., & Stratton, J. R. (1995) · Circulation · doi:10.1161/01.cir.92.10.2984 · Cited by 86
Self-citation
The cardiac output--oxygen uptake relationship of men during graded bicycle ergometry.
Faulkner, J. A., Heigenhauser, G. J. F., & Schork, M. A. (1977) · PubMed · Cited by 85
Complexes between tissue-type plasminogen activator and proteinase inhibitors in human plasma, identified with an immunoradiometric assay.
Rijken, D. C., Juhan-Vague, I., & Collen, D. (1983) · PubMed · Cited by 79
Self-citation
Tissue plasminogen activator in thrombolytic therapy
(1987) · European Journal of Medicinal Chemistry · doi:10.1016/0223-5234(87)90281-9 · Cited by 75
Tissue-type plasminogen activator (t-PA) : physiological and clinical aspects
Kluft, C. (1988) · TNO Repository · Cited by 72
Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells.
Coleman, P. L., Patel, P. D., Cwikel, B. J., Rafferty, U. M., Sznycer-Laszuk, R., & GELEHRTER, T. D. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35668-5 · Cited by 69
Catabolism of tissue-type plasminogen activator (t-PA), its variants, mutants and hybrids
Krause, J. (1988) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(88)90026-4 · Cited by 69
Liver Blood Flow as a Major Determinant of the Clearance of Recombinant Human Tissue-Type Plasminogen Activator
de Boer, A., Kluft, C., Kroon, J. M., Kasper, F. J., Schoemaker, R. C., Pruis, J., Breimer, D. D., Soons, P. A., EMEIS, J. J., & Cohen, A. F. (1992) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1648385 · Cited by 67
LDL receptor-related protein (LRP): a multiligand receptor
Strickland, D. K., Kounnas, M. Z., Williams, S. E., & Argraves, W. S. (1994) · Fibrinolysis and Proteolysis · doi:10.1016/0268-9499(94)90718-8 · Cited by 62
Fibrinolysis in Normal Subjects - Comparison Between Plasminogen Activator Inhibitor and Other Components of the Fibrinolytic System
Nicoloso, G., Hauert, J., Kruithof, E. K. O., van Melle, G., & Bachmann, F. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1642775 · Cited by 61
On the Role of C1-Inhibitor as Inhibitor of Tissue-type Plasminogen Activator in Human Plasma
Huisman, L. G. M., van Griensven, J. M. T., & Kluft, C. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1653798 · Cited by 53
Renal and Hepatic Handling of Endogenous Tissue-Type Plasminogen Activator (t-PA) and Its Inhibitor in Man
Brommer, E. J. P., Derkx, F. H. M., Schalekamp, M. A. D. H., Dooijewaard, G., & van der Klaauw, M. M. (1988) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647505 · Cited by 52
A kinetic model of the circulatory regulation of tissue plasminogen activator during exercise, epinephrine infusion, and endurance training
Chandler, W. L., Levy, W. A., Veith, R., & Stratton, J. (1993) · Blood · doi:10.1182/blood.v81.12.3293.3293 · Cited by 51
Self-citation
Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complexes in plasma of control subjects and of patients with increased t-PA or PAI-1 levels
Alessi, M., Juhan-Vague, I., Declerck, P. J., Anfosso, F. J., Gueunoun, E., & Collen, D. (1990) · Thrombosis Research · doi:10.1016/0049-3848(90)90235-5 · Cited by 49
Self-citation
Functions of the Vascular System
Witzleb, E. (1989) · Human Physiology · doi:10.1007/978-3-642-73831-9_20 · Cited by 47
A Kinetic Model of the Circulatory Regulation of Tissue Plasminogen Activator
Chandler, W. L. (1991) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1646415 · Cited by 46
Self-citation
Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.
Wing, L. R., Gm, H., Bennett, B., & Booth, N. A. (1991) · PubMed · Cited by 39
Increase of tissue plasminogen activator in limbs during venous occlusion: a simple haemodynamic model.
Keber, D., Blinc, A., & Fettich, J. (1990) · PubMed · Cited by 29
lncrease of Tissue Plasminogen Activator in Limbs During Venous Occlusion : A Simple Haemodynamic Model
Keber, D., Blinc, A., & Fettich, J. (1990) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1647332 · Cited by 26
Hemostatic Factors and the Risk of Myocardial Infarction
Otto, C., & Richter, W. O. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508103330616 · Cited by 25
Venous Occlusion Does Not Release von Willebrand Factor, Factor VIII or PAI-1 from Endothelial Cells – The Importance of Consensus on the Use of Correction Factors for Haemoconcentration
Wieczorek, I., Ludlam, C. A., & MacGREGOR, I. R. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651559 · Cited by 23
Clearance receptors for tissue-type plasminogen activator.
Camani, C., & Kruithof, E. K. O. (1994) · PubMed · Cited by 21
Molecular forms of plasminogen activator inhibitor-1 (PAI-1) and tissue-type plasminogen activator (t-PA) in human plasma
Alessi, M., Juhan-Vague, I., Declerck, P. J., & Collen, D. (1991) · Thrombosis Research · doi:10.1016/0049-3848(91)90148-p · Cited by 18
Self-citation
Relation between Plasma PAI Activity and Adipsin Levels
Alessi, M., Parrot, G., Gueunoun, E., Seelles, V., Vague, P., & Juhan-Vague, I. (1995) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1649906 · Cited by 14
Self-citation
Isolation and Characterization of Tissue-Type Plasminogen Activator–Binding Proteoglycans From Human Umbilical Vein Endothelial Cells
Böhm, T., Geiger, M., & Binder, B. R. (1996) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.16.5.665 · Cited by 13
The pharmacokinetics of recombinant double-chain t-PA (duteplase): Effects of bolus injection, infusions, and administration by weight in patients with myocardial infarction
Koster, R. W., Cohen, A. F., Kluft, C., Kasper, F. J., van der Wouw, P. A., & Weatherley, B. C. (1991) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1991.136 · Cited by 12
Functions of the Vascular System
Witzleb, E. (1983) · Human Physiology · doi:10.1007/978-3-642-96714-6_18 · Cited by 7

Research works printed but not linked: 6

10.1161/circ.92.10.2984 · DOI
10.1161/circ.94.9.2057 · DOI
10.1161/circ.88.5.8222095 · DOI
10.1161/circ.77.3.2449299 · DOI
10.1182/blood.V64.4.907.907 · DOI
10.1161/atvb.16.5.665 · DOI

Sorted by citations

High Plasminogen Activator Inhibitor and Tissue Plasminogen Activator Levels in Plasma Precede a First Acute Myocardial Infarction in Both Men and Women: Evidence for the Fibrinolytic System as an Independent Primary Risk Factor
Thögersen, A. M., Jansson, J.-H., Boman, K., Nilsson, T. K., Weinehall, L., Huhtasaari, F., & Hallmans, G. (1998) · Circulation · doi:10.1161/01.cir.98.21.2241 · Cited by 602
Diabetes mellitus as a prothrombotic condition
Grant, P. J. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2007.01824.x · Cited by 443
Nontraditional Risk Factors and Biomarkers for Cardiovascular Disease: Mechanistic, Research, and Clinical Considerations for Youth
Balagopal, P., de Ferranti, S. D., Cook, S., Daniels, S. R., Gidding, S. S., Hayman, L. L., McCrindle, B. W., Mietus‐Snyder, M., & Steinberger, J. (2011) · Circulation · doi:10.1161/cir.0b013e31821c7c64 · Cited by 363
Adipokines, Inflammation, and Visceral Adiposity across the Menopausal Transition: A Prospective Study
Lee, C. G., Carr, M. C., Murdoch, S. J., Mitchell, E. S., Woods, N. F., Wener, M. H., Chandler, W. L., Boyko, E. J., & Brunzell, J. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0701 · Cited by 279
Self-citation
Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects.
Kruszynska, Y. T., Yu, J., Olefsky, J. M., & Sobel, B. E. (2000) · Diabetes · doi:10.2337/diabetes.49.4.633 · Cited by 184

See all 245

Authors: Chandler, W. L., Alessi, M. C., Aillaud, M. F., Henderson, P., Vague, P., & Juhan-Vague, I.
Affiliations: Inserm (FR)
ORCID: Chandler, W. L.
Alessi, M. C.
Venue: Circulation
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 1997-08-05
Volume: 96
Issue: 3
Pages: 761-768
ISSN: 0009-7322 (ISSN-L)
1524-4539
DOI: 10.1161/01.cir.96.3.761
OpenAlex: W1998362943
Cited by: 245
References: 54
Citations by year: 2026: 6 · 2025: 9 · 2024: 7 · 2023: 7 · 2022: 10 · 2021: 11 · 2020: 9 · 2019: 5 · 2018: 4 · 2017: 4 · 2016: 14 · 2015: 5 · 2014: 8 · 2013: 9 · 2012: 6
FWCI: 6.72
Type: journal article
Language: en
Open access: closed
Locations: Circulation (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
Health Sciences › Medicine › Hematology › Coagulation, Bradykinin, Polyphosphates, and Angioedema
Keywords: tissue plasminogen activator, plasminogen activator inhibitor-1, t-PA/PAI-1 complex, plasma clearance, pharmacokinetics, hepatic clearance, fibrinolysis, two-compartment model
MeSH terms: Adult, Antigens, Computer Simulation, Female, Humans, Male, Middle Aged, Models, Biological, Tissue Plasminogen Activator, Plasminogen Activator Inhibitor 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Clearance of Tissue Plasminogen Activator (TPA) and TPA/Plasminogen Activator Inhibitor Type 1 (PAI-1) Complex: Relationship to Elevated TPA Antigen in Patients With High PAI-1 Activity Levels

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks